

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 16, 2019

INDEX

Editorial Board

A. Seth	Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
G.J. Delinasios	Managing Editor and Executive Publisher International Institute of Anticancer Research, Athens, Greece
L.A. Aaltonen	Department of Medical Genetics, University of Helsinki, Finland
R. Abagyan	The Scripps Research Institute, La Jolla, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
R. Clarke	Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
T. Efferth	Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
N.A. Ellis	Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
A. Facchetti	Fondazione CNAO, Pavia, Italy
J.A. Fernandes-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst	Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
D.S. Gerhard	NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
G. Glinsky	Institute of Engineering in Medicine, University of California, San Diego, CA, USA
T.R. Golub	Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
J. Gordon	Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
C.-H. Heldin	Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel	Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
T.H.M. Huang	Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
S.C. Jhanwar	Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
W.G. Jiang	Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK
J. Ju	Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
A. Kallioniemi	Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi	Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khalili	College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
D.G. Kieback	Helios Medical Center Schleswig, Schleswig, Germany
S.D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
Y. T. Kwon	Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
B. Léylund-Jones	Avera Cancer Institute, Sioux Falls, SD, USA
P. Lichter	Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom	Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec	Department of Pediatrics, University of Vienna, Austria
J. Lyons-Weiler	Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
P.J. McCormick	The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
F. Mitelman	Department of Clinical Genetics, University Hospital, Lund, Sweden
C. Nicot	Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
L. O'Driscoll	School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
C.D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

J.S. Rader	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
B.W. Schäfer	Department of Oncology, University Children's Hospital, Zurich, Switzerland
J. Schneider	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
O.J. Semmes	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford	Cancer Science Division, Southampton General Hospital, Southampton, UK
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
U.H. Weidle	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
A.T. Yeung	Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: www.iar-anticancer.org; www.cgp.iarjournals.org.

Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: journals@iar-anticancer.org. Managing Editor: editor@iar-anticancer.org.

Web: www.iar-anticancer.org; www.cgp.iarjournals.org.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 16, 2019.

307 Hospital, Academy of Military Medical Sciences (AMMS), Beijing, P.R. China
 American Cancer Society, Atlanta, GA, U.S.A.
 American Heart Association, Dallas, TX, U.S.A.
 Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan
 Argentine National Cancer Institute (INC), Buenos Aires, Argentina
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy

Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
 BIO & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
 Breast Cancer Hope Foundation, London, U.K.

Cancer Society of New Zealand (CSNZ), Wellington, New Zealand
 Cancer Society Tissue Bank (CSTB), Christchurch, New Zealand
 Canterbury Medical Research Foundation (CMRF), Christchurch, New Zealand
 Center for Computational Science and Engineering, Southern University of Science and Technology, Shenzhen, P.R. China
 Center for Women in Science, Engineering and Technology (WISSET), Gangnam-gu, Republic of Korea
 Cohort Profile: Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen, Thailand
 Czech Health Research Council, Prague, Czech Republic

Daiwa Securities Health Foundation, Tokyo, Japan
 DEKART Proteomics Laboratory, Kocaeli University Medical School, Kocaeli, Turkey
 Délégation à la Recherche Clinique et à l'Innovation (DRCI) CHU St-Etienne, Saint-Priest-en-Jarez, France
 Department of Haematology, Oslo University Hospital, Oslo, Norway
 Department of Human Morphology and Embryology, Division of Histology and Embryology, Wrocław Medical University, Wrocław, Poland

Department of Pathology, Massachusetts General Hospital, Boston, MA, U.S.A.
 Department of Urology, Hospital de Clínicas “José de San Martín”, Buenos Aires, Argentina
 Department of Veterans Affairs, Washington, DC, U.S.A.

Eli Lilly Japan K.K., Kobe, Japan

Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
 Fujian Provincial Health Department Young and Middle-aged Talents Training Project, Fujian Province, P.R. China
 Fujian Provincial Natural Science Foundation, Fujian Province, P.R. China
 Fundación Honorio Bigand, Buenos Aires, Argentina
 Futuro in Ricerca (FIRB)/ Medical Research in Italy (MERIT) Project, Ministry of Economic Development (MISE), Italy

Gestione di un servizio integrato multicentrico di diagnostica e terapia personalizzata in oncologia (GeSeTon), Ministry of Economic Development (MISE), Italy
 Guangdong and Shenzhen Research Funds, P.R. China

H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
 Hampden-Sydney College Research Grant, Arthur Vining Davis Endowment, Ponte Vedra Beach, FL, U.S.A.
 Hampden-Sydney College, Hampden Sydney, VA, U.S.A.
 Hellenic Cooperative Oncology Group, Athens, Greece
 Hubei Provincial Department of Science & Technology, Wuhan, P.R. China
 Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Indiana Clinical and Translational Sciences Institute
 Italian Ministry of Education, University and Research (MIUR), Rome, Italy
 Italian Ministry of Health, Rome, Italy

Japan Orthopaedic and Traumatology Research Foundation Inc., Tokyo, Japan
 Japan Society for the Promotion of Science, (JSPS), Tokyo, Japan

- Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan
- Jeffress Trust Awards Program in Interdisciplinary Research Grant, Thomas F. and Kate Miller Jeffress Memorial Trust, U.S.A.
- Joint Funds for the Innovation of Science and Technology, Fujian Province, P.R. China
- KKU Publication Clinic, Bangkok, Khon Kaen, Thailand
- KoreaBiobank Network-KNUH, Republic of Korea
- Lung Cancer Proteomics LLC, Michigan City, IN, U.S.A.
- Mackenzie Charitable Foundation, Ashburton, New Zealand
- Maurice L. Mednick Memorial Fellowship, Virginia Foundation for Independent Colleges (VFIC), Richmond, VA, U.S.A.
- Mid-Career Grant, Thailand Research Fund, Bangkok, Thailand
- Ministry of Health of the Czech Republic, Prague, Czech Republic
- Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
- Moffitt Molecular Genomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
- National Basic Research Program of China, P.R. China
- National Biobank of Korea-Kyungpook National University Hospital (KNUH), Daegu, Republic of Korea
- National Center for Advancing Translational Sciences (NCATS), NIH, Bethesda, MD, U.S.A.
- National Clinical Key Specialty Construction Project (General Surgery) of China, P.R. China
- National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.
- National Institutes of Health (NIH), Bethesda, MD, U.S.A.
- National Key Research and Development Program of China, P.R. China
- National Natural Science Foundation of China, Guangdong, P.R. China
- National Science Centre, Warsaw, Poland
- National Taiwan University, Taipei, Taiwan, R.O.C.
- NCI-designated Comprehensive Cancer Center, U.S.A.
- Norwegian Radium Hospital Foundation, Norway
- OITA Cancer Research Foundation, Oita, Japan
- Priority Issue on Post-K Computer, Japan
- Project of Science and Technology Research Program, Fujian Province, P.R. China
- Proteomics Core Facility CEQUIBIEM, Buenos Aires, Argentina
- Radiumhospitalets Legater, Oslo, Norway
- Research Project of Shanghai Municipal Health and Family Planning Commission, Shanghai, P.R. China
- Scientific Research Unit, Kocaeli University, Kocaeli, Turkey
- Shanghai Municipal Planning Commission of Science and Research Fund, Shanghai, P.R. China
- Shenzhen Peacock Plan, P.R. China
- Special Project on Precision Medicine under the National Key R&D Program, P.R. China
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taiwan Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
- The Cancer Genome Atlas Program (TCGA) Research Network, National Cancer Institute, NIH, Bethesda, MD, U.S.A.
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Tissue Core Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
- Total Cancer Care Consortium Tissue Core Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
- Tumorothèque/Centre de Ressources Biologiques de CHU Saint-Etienne, Saint-Priest-en-Jarez, France
- Undergraduate Science Research Fellowships, Virginia Foundation for Independent Colleges (VFIC), Richmond, VA, U.S.A.
- US Army Medical Research and Materiel Command (USAMRMC), Fort Detrick, MD, U.S.A.
- Veterans Administration Medical Center, Memphis, TN, U.S.A.
- Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania
- Virginia Academy of Science Undergraduate Research Grant, Richmond, VA, U.S.A.
- Virginia's Commonwealth Health Research Board, Richmond, VA, U.S.A.

Contents, Volume 16, 2019

Number 1, January-February

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. U.H. WEIDLE, A. EPP, F. BIRZELE, U. BRINKMANN (<i>Penzberg, Germany; Basel, Switzerland</i>)	1
Multiregion Genomic Analysis of Serially Transplanted Patient-derived Xenograft Tumors. K. SATO, A. NIIDA, T. MASUDA, D. SHIMIZU, T. TOBO, Y. KURODA, H. EGUCHI, T. NAKAGAWA, Y. SUZUKI, K. MIMORI (<i>Oita; Fukuoka; Tokyo; Chiba, Japan</i>)	21
Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia. P.A. SACCA, O.N. MAZZA, C. SCORTICATI, G. VITAGLIANO, G. CASAS, J.C. CALVO (<i>Buenos Aires, Argentina</i>)	29
Isoforms of Ionotropic Glutamate Receptor GRIK2 Induce Senescence of Carcinoma Cells. V.K. ZHAWAR, R.P. KANDPAL, R.S. ATHWAL (<i>Philadelphia, PA; Pomona, CA, USA</i>)	59
Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer. S. LEHRER, P.H. RHEINSTEIN (<i>New York, NY; Severna Park, MD, USA</i>)	65
MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 <i>via</i> PAX3. R. FUJII, E. OSAKA, K. SATO, Y. TOKUHASHI (<i>Tokyo, Japan</i>)	71
A Comprehensive Proteome Analysis of Peripheral Blood Mononuclear Cells (PBMCs) to Identify Candidate Biomarkers of Pancreatic Cancer. H. LI, Y. MAO, Y. XIONG, H.H. ZHAO, F. SHEN, X. GAO, P. YANG, X. LIU, D. FU (<i>Shanghai, PR China</i>)	81
Does <i>SF3B1/TET2</i> Double Mutation Portend Better or Worse Prognosis Than Isolated <i>SF3B1</i> or <i>TET2</i> Mutation? J. SONG, L. MOSCINSKI, H. ZHANG, X. ZHANG, M. HUSSAINI (<i>Tampa, FL, USA</i>)	91

Number 2, March-April 2019

Review: MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. U.H. WEIDLE, F. BIRZELE, A. NOPORA (<i>Penzberg, Germany; Basel, Switzerland</i>)	99
Correlation of <i>TERT</i> and Stem Cell Markers in the Context of Human Breast Cancer. U. WAZIR, M.M.A.W. ORAKZAI, T.A. MARTIN, W.G. JIANG, K. MOKBEL (<i>London; Cardiff, UK; Peshawar, Pakistan</i>)	121
Serum Proteomic Signatures of Male Breast Cancer. E. ZOGRAFOS, A.K. ANAGNOSTOPOULOS, A. PAPADOPOULOU, E. LEGAKI, F. ZAGOURI, E. MARINOS, G.T. TSANGARIS, M. GAZOULI (<i>Athens, Greece</i>)	129
MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. P. AHMAD, J. SANA, M. SLAVIK, D. GURIN, L. RADOVA, N.A. GABLO, T. KAZDA, P. SMILEK, Z. HORAKOVA, B. GAL, M. HERMANOVA, P. SLAMPA, O. SLABY (<i>Brno, Czech Republic</i>)	139

Number 3, May-June 2019

Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype. S. LEHRER, S. GREEN, F.R. DEMBITZER, P.H. RHEINSTEIN, K.E. ROSENZWEIG (<i>New York, NY; Severna Park, MD, USA</i>)	147
---	-----

Gene Expression Comparison Between the Primary Tumor and its Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma: A Pilot Study. G. KARPATHIU, M.-L. STACHOWITZ, J.M. DUMOLLARD, M. GAVID, M. FROUDARAKIS, J.M. PRADES, M. PEOC'H (<i>Saint-Étienne, France</i>)	155
Transcriptomic Characterization, Chemosensitivity and Regulatory Effects of Exosomes in Spontaneous EMT/MET Transitions of Breast Cancer Cells. E. BIGAGLI, L. CINCI, M. D'AMBROSIO, C. LUCERI (<i>Florence, Italy</i>)	163
Molecular Genetic Characterization of Acute Myeloid Leukemia With Trisomy 4 as the Sole Chromosome Abnormality. S. TORKILDSEN, L. GORUNOVA, S. HEIM, G.E. TJØNNFJORD, S. SPETALEN, B. RISBERG, H.T.T. TRAN, I. PANAGOPOULOS (<i>Oslo; Lørenskog, Norway</i>)	175
Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome. B.E. KRAZINSKI, J. KIEWISZ, A. SLIWINSKA-JEWSIEWICKA, A.E. KOWALCZYK, J. GRZEGRZOLKA, J. GODLEWSKI, P. KWIATKOWSKI, P. DZIEGIEL, Z. KMIĘC (<i>Olsztyn; Wrocław; Gdańsk, Poland</i>)	179
Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. G. LAZARIDIS, V. KOTOULA, E. VRETTU, I. KOSTOPOULOS, K. MANOUSOU, K. PAPADOPOULOU, E. GIANNOULATOU, M. BOBOS, M. SOTIROPOULOU, G. PENTHEROUDAKIS, I. EFSTRATIOU, A. PAPOUDOU-BAI, A. PSYRRI, C. CHRISTODOULOU, H. GOGAS, A. KOUTRAS, E. TIMOTHEADOU, D. PECTASIDES, F. ZAGOURI, G. FOUNTZILAS (<i>Thessaloniki; Athens; Ioannina; Piraeus; Patras, Greece; Darlinghurst; Kensington, NSW, Australia</i>)	195
Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Z. LI, YULING CHEN, W. REN, S. HU, Z. TAN, Y. WANG, YAOWEN CHEN, J. ZHANG, J. WU, T. LI, J. XU, X. YING (<i>Beijing; Wuhan; Fuzhou, PR China</i>)	207
Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing. B. ZHENG, Y. QU, J. WANG, Y. SHI, W. YAN (<i>Shanghai; Beijing, PR China</i>)	221

Number 4, July-August 2019

Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients. C. GOEBEL, C.L. LOUDEN, R. MCKENNA Jr., O. ONUGHA, A. WACHTEL, T. LONG (<i>Mountain View; Santa Monica; Los Angeles, CA; San Antonio, TX; Hebron, IN, USA</i>)	229
The Association of a Novel Identified <i>VDR</i> SNP With Prostate Cancer in African American Men. M.R. DAREMPOURAN, D. BEYENE, V. APPREY, T.J. NAAB, O.O. KASSIM, R.L. COPELAND JR, Y.M. KANAAN (<i>Washington, DC, USA</i>)	245
Gene Expression Profiles Induced by High-dose Ionizing Radiation in MDA-MB-231 Triple-negative Breast Cancer Cell Line. V. BRAVATÀ, F.P. CAMMARATA, L. MINAFRA, R. MUSSO, G. PUCCI, M. SPADA, I. FAZIO, G. RUSSO, G.I. FORTE (<i>Cefalù; Palermo, Italy</i>)	257
STK11 p.G270W: A Novel Mutation Detected in a Case of MSI High Mixed Medullary–Mucinous Carcinoma of the Transverse Colon. M. SHAHID, D. WANG, J. SALLER, E. RYZHOVA, D. QIN, A. MAGLIOCCO, D. COPPOLA (<i>Tampa; Bradenton, FL, USA</i>)	267
Comparative Proteome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteogenomics. O.K. KWON, Y.-S. HA, J.N. LEE, S. KIM, H. LEE, S.Y. CHUN, T.G. KWON, S. LEE (<i>Daegu; Bucheon, Republic of Korea</i>)	273
Contribution of Matrix Metalloproteinase-2 Promoter Genotypes to Nasopharyngeal Cancer Susceptibility and Metastasis in Taiwan. S.-W. HSU, C.-L. GONG, H.-M. HSU, C.-C. CHAO, Y.-C. WANG, W.-S. CHANG, Y.-T. TSAI, L.-C. SHIH, C.-W. TSAI, D.-T. BAU (<i>Taichung; Taipei, Taiwan, ROC</i>)	287

Fusion of the Genes <i>WWTR1</i> and <i>FOSB</i> in Pseudomyogenic Hemangioendothelioma. I. PANAGOPOULOS, I. LOBMAIER, L. GORUNOVA, S. HEIM (<i>Oslo, Norway</i>)	293
---	-----

Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. A. NESIU, A.M. CIMPEAN, R.A. CEAUSU, A. ADILE, I. IOIART, C. PORTA, M. MAZZANTI, T.C. CAMEROTA, M. RAICA (<i>Arad; Timisoara, Romania; Pavia; Milan, Italy</i>)	299
---	-----

Number 5,

September-October 2019

EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. J. SALLER, S. SEYDAFKAN, M. SHAHID, M. GADARA, M. CIVES, S.A. ESCHRICH, D. BOULWARE, J.R. STROSBERG, N. AEJAZ, D. COPPOLA (<i>Tampa, FL; Indianapolis, IN, USA</i>).....	309
---	-----

Co-culture With Human Breast Adipocytes Differentially Regulates Protein Abundance in Breast Cancer Cells. R.L.I. CRAKE, E. PHILLIPS, T. KLEFFMANN, M.J. CURRIE (<i>Christchurch; Dunedin, New Zealand</i>)	319
---	-----

Association of Leukemia Target Genes <i>Tet2</i> , <i>Bcl2</i> , and <i>Slc23a2</i> in Vitamin C Pathways. J. LI, W. ZHANG, W. LIU, J. RONG, Y. CHEN, W. GU, W. ZHANG (<i>Memphis, TN; Austin, TX, USA; Shijiazhuang; Heilongjiang; Beijing, PR China</i>).....	333
---	-----

Fusion of the Genes <i>PHF1</i> and <i>TFE3</i> in Malignant Chondroid Syringoma. I. PANAGOPOULOS, L. GORUNOVA, M. LUND-IVERSEN, A. BASSAROVA, S. HEIM (<i>Oslo, Norway</i>).....	345
---	-----

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients. J. KOVACOVA, J. JURACEK, A. POPRACH, J. KOPECKY, O. FIALA, M. SVOBODA, P. FABIAN, L. RADOVA, P. BRABEC, T. BUCHLER, O. SLABY (<i>Brno; Hradec Kralove; Pilsen; Prague, Czech Republic</i>).....	353
---	-----

Fusion of the <i>COL1A1</i> and <i>FYN</i> Genes in Epithelioid Osteoblastoma. I. PANAGOPOULOS, L. GORUNOVA, I. LOBMAIER, M. LUND-IVERSEN, K. ANDERSEN, A. HOLTH, B. BJERKEHAGEN, S. HEIM (<i>Oslo, Norway</i>)	361
---	-----

Mts1 Up-regulation is Associated With Aggressive Pathological Features in Thyroid Cancer. M.G. CHEON, Y.W. SON, J.-H. LEE, H.H. JANG, Y.S. CHUNG (<i>Incheon, Republic of Korea</i>)	369
--	-----

Comparative Proteome Analysis of Breast Cancer Tissues Highlights the Importance of Glycerol-3-phosphate Dehydrogenase 1 and Monoacylglycerol Lipase in Breast Cancer Metabolism. K. KARAOSMANOGLU YONETEN, M. KASAP, G. AKPINAR, A. GUNES, B. GUREL, N.Z. UTKAN (<i>Kocaeli, Turkey</i>).....	377
--	-----

Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing. B. ZHENG, S. ZHANG, W. CAI, J. WANG, T. WANG, N. TANG, Y. SHI, X. LUO, W. YAN (<i>Shanghai, PR China</i>)	399
--	-----

Number 6, November-December 2019

MyD88 Regulates LPS-induced NF- κ B/MAPK Cytokines and Promotes Inflammation and Malignancy in Colorectal Cancer Cells. G. ZHU, Z. CHENG, C. LIN, R.M. HOFFMAN, Y. HUANG, S.R. SINGH, W. ZHENG, S. YANG, J. YE (<i>Fuzhou, PR China; San Diego, CA; Frederick, MD, USA</i>)	409
--	-----

Whole Transcriptomic Analysis of Apigenin on TNF α Immuno-activated MDA-MB-231 Breast Cancer Cells. D. BAUER, E. MAZZIO, K.F.A. SOLIMAN (<i>Tallahassee, FL, USA</i>).....	421
---	-----

MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation. A.A. ASSIRI, N. MOURAD, M. SHAO, P. KIEL, W. LIU, T.C. SKAAR, B.R. OVERHOLSER (<i>West Lafayette; Fort Wayne; Indianapolis, IN; Detroit, MI, USA; Abha, Kingdom of Saudi Arabia</i>).....	433
--	-----

Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II. I. SKIRNISDOTTIR, H. AKERUD, T. SEIDAL, I. SUNDSTROM-POROMAA (<i>Uppsala; Halmstad, Sweden</i>)	443
Review: Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical <i>In Vivo</i> Models. U.H. WEIDLE, F. BIRZELE, A. NOPORA (<i>Penzberg, Germany; Basel, Switzerland</i>)	451
Seeking mTORC1 Inhibitors Through Molecular Dynamics Simulation of Arginine Analogs Inhibiting CASTOR1. L. SUN, X. LI, J. PAN, J. MAO, Y. YUAN, D. WANG, W. SUN, G.R.F. KRUEGER, G. WANG (<i>Shenzhen; Shanghai, PR China; Houston, TX, USA</i>)	465
Regulation of <i>REG4</i> Expression and Prediction of 5-Fluorouracil Sensitivity by CDX2 in Ovarian Mucinous Carcinoma. I. KOH, S. NOSAKA, M. SEKINE, J. SUGIMOTO, E. HIRATA, Y. KUDO (<i>Hiroshima, Japan</i>)	481
The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness. K.M. HARGADON, B. GYÖRFFY, E.W. STRONG, B.D. TARNAI, J.C. THOMPSON, D.Z. BUSHHOUSE, C.E. JOHNSON, C.J. WILLIAMS (<i>Hampden-Sydney, VA, USA; Budapest, Hungary</i>)	491
Acquisition of Invasiveness by Breast Adenocarcinoma Cells Engages Established Hallmarks and Novel Regulatory Mechanisms. H. MOUSA, M. ELGAMAL, R.G. MAREI, N. SOUCHELNYTSKYI, K.-W. LIN, S. SOUCHELNYTSKYI (<i>Doha, Qatar; Uppsala; Solna, Sweden</i>)	505
Synergism of Adipocytokine Profile and <i>ADIPOQ/TNF-α</i> Polymorphisms in NAFLD-associated MetS Predict Colorectal Liver Metastases Outgrowth. R. DIVELLA, A. DANIELE, R. DE LUCA, A. MAZZOCCA, E. RUGGIERI, E. SAVINO, P. CASAMASSIMA, M. SIMONE, C. SABBA, A. PARADISO (<i>Bari, Italy</i>)	519
Genotyping <i>KRAS</i> and <i>EGFR</i> Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. H. LINARDOU, V. KOTOULA, G. KOUVATSEAS, G. MOUNTZIOS, V. KARAVASILIS, E. SAMANTAS, A. KALOGERA-FOUNTZILA, D. TELEVANTOU, K. PAPADOPOULOU, X. MAVROPOULOU, E. DASKALAKI, T. ZARAMBOUKAS, I. EFSTRATIOU, S. LAMPAKI, G. RALLIS, E. RES, K.N. SYRIGOS, P.A. KOSMIDIS, D. PECTASIDES, G. FOUNTZILAS (<i>Athens; Thessaloniki, Greece</i>)	531
PRIMA-1 ^{MET} Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells. C. PIYAWAJANUSORN, Y. KITTIRAT, P. SA-NGIAMWIBOOL, A. TITAPUN, W. LOILOME, N. NAMWAT (<i>Khon Kaen, Thailand</i>)	543
Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer. G.H. HAN, D.B. CHAY, J.M. YI, H. CHO, J.-Y. CHUNG, J.-H. KIM (<i>Seoul; Busan, Republic of Korea; Bethesda, MD, USA</i>)	553
Genetic Characterization of Myoid Hamartoma of the Breast. I. PANAGOPOULOS, L. GORUNOVA, H.K. ANDERSEN, T.D. PEDERSEN, J. LØMO, M. LUND-IVERSEN, F. MICCI, S. HEIM (<i>Oslo, Norway</i>)	563
Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Y.-H. FENG, C.-L. TUNG, Y.-C. SU, C.-J. TSAO, T.-F. WU (<i>Tainan, Taiwan, ROC</i>)	569
The Activity of Immune Checkpoint Inhibition in <i>KRAS</i> Mutated Non-small Cell Lung Cancer: A Single Centre Experience. J. TORRALVO, A. FRIEDLAENDER, V. ACHARD, A. ADDEO (<i>Geneva, Switzerland</i>)	577
Proteomic Analysis of Primary Colon Cancer and Synchronous Solitary Liver Metastasis. E.-K. KIM, M.-J. SONG, Y. JUNG, W.-S. LEE, H.H. JANG (<i>Incheon, Republic of Korea</i>)	583
DNA Replication Inhibitor Geminin and Retinoic Acid Signaling Participate in Complex Interactions Associated With Pluripotency. S. CHAMPERIS TSANIRAS, G.J. DELINASIOS, M. PETROPOULOS, A. PANAGOPOULOS, A.K. ANAGNOSTOPOULOS, M. VILLIOU, D. VLACHAKIS, V. BRAVOU, G.T. STATHOPOULOS, S. TARAVIRAS (<i>Patras; Kapandriti; Athens, Greece; Cold Spring Harbor, NY, USA</i>)	593
Index	603

Subject Index

(Figures refer to page numbers)

- 5-fluorouracil, CDX2, REG4, mucinous carcinoma, ovarian cancer, 481
- Acquired resistance, cetuximab, colorectal cancer, transcriptome alteration, regulatory networks, 207
- Acute myeloid leukemia, trisomy 4, targeted sequencing, mutations, *NPM1*, 175
- Adiponectin, leptin, $\text{tNF-}\alpha$, colorectal cancer, metabolic syndrome, obesity, NAFLD, 519
- Adjuvant chemotherapy, PTEN immunohistochemistry, heterogeneity, discordance, PI3K pathway, HER2-positive breast cancer, trastuzumab, 195
- Alternative pathways, vitamin C, leukemia, eQTL mapping, key genes, 333
- Antagomirs, *KRAS* oncogene, miR sponges, orthotopic xenograft models, therapeutic miR-related agents, transforming growth factor β signaling, tumor suppressor genes, review, 451
- Apigenin, triple-negative breast cancer, $\text{tNF}\alpha$, differential gene expression analysis, immune signaling, 421
- Apoptosis, cellular senescence, PRIMA-1^{MET}, cholangiocarcinoma, 543
- Benign prostate hyperplasia, periprostatic adipose tissue, fat tissue, secretome, proteomic, prostate cancer, microenvironment, 29
- Biomarkers, early stage lung cancer, proteomics, immunoassay, detection, diagnosis, non-small cell lung cancer, 229
- Blood, PBMC, iTRAQ, SWATH, pancreatic cancer, 81
- BMI, p27, non-serous tumors, ovarian cancer, FIGO-stages I-II, 443
- Breast cancer proteomics, monoacylglycerol lipase, glycerol-3-phosphate dehydrogenase, 377
- Breast cancer, cancer-associated adipocytes, CAA, iTRAQ, metabolism, tumour microenvironment, 319
- Breast cancer, epithelial–mesenchymal transition (EMT), mesenchymal–epithelial transition (MET), metastasis, chemoresistance, exosomes, 163
- Breast cancer, invasiveness, proteomics, systems biology, 505
- Breast cancer, microRNA, HERG, miR-362-3p, voltage-gated potassium channels, 433
- Breast cancer, survival, von Willebrand factor, the Cancer Genome Atlas, coagulation, 147
- Breast cancer, telomeres, pluripotency, cell cycle, 121
- CAA, cancer-associated adipocytes, iTRAQ, breast cancer, metabolism, tumour microenvironment, 319
- Cancer vaccines, polio virus, colorectal cancer, the UCSC Genome Browser, the Cancer Genome Atlas, 65
- Cancer-associated adipocytes, CAA, iTRAQ, breast cancer, metabolism, tumour microenvironment, 319
- Cancer, mTOR, CASTOR1, molecular dynamics simulation, 465
- Cancer, senescence, GRIK2, GLUR6, carcinoma, gene transfer, 59
- Carcinoma, senescence, GRIK2, GLUR6, cancer, gene transfer, 59
- CASTOR1, mTOR, cancer, molecular dynamics simulation, 465
- CDX2, 5-fluorouracil, REG4, mucinous carcinoma, ovarian cancer, 481
- Cell cycle, telomeres, pluripotency, breast cancer, 121
- Cellular senescence, PRIMA-1^{MET}, apoptosis, cholangiocarcinoma, 543
- Cetuximab, acquired resistance, colorectal cancer, transcriptome alteration, regulatory networks, 207
- Chemoresistance, breast cancer, epithelial–mesenchymal transition (EMT), mesenchymal–epithelial transition (MET), metastasis, exosomes, 163
- Chloride Intracellular Channel 1 (CLIC1), clear cell renal cell carcinoma (cc RCC), 299
- Cholangiocarcinoma, cellular senescence, PRIMA-1^{MET}, apoptosis, 543
- Chromosome translocation, myoid hamartoma of the breast, cytogenetics, HMGA2 rearrangement, fluorescence *in situ* hybridization, RNA sequencing, reverse transcription polymerase chain reaction, sanger sequencing, 563
- Claudin, maspin, scca, survivin, egfr, vegf, hpv, p16, 155
- Clear cell renal cell carcinoma (cc RCC), Chloride Intracellular Channel 1 (CLIC1), 299
- Clear cell renal cell carcinoma, DDR1, miR-199a-5p, miR-199b-5p, 179
- Coagulation, breast cancer, survival, von Willebrand factor, the Cancer Genome Atlas, 147
- COL1A1-FYN* fusion gene, epithelioid osteoblastoma, *COL1A1*, *FYN*, RNA sequencing, 361
- COL1A1*, epithelioid osteoblastoma, *FYN*, *COL1A1-FYN* fusion gene, RNA sequencing, 361
- Colon cancer, differentially expressed proteins, gene ontology, liver metastatic cancer, mass spectrometry analysis, protein-protein interactions, 583
- Colon cancer, MSI, medullary, mucinous, STK11, mutation, 267
- Colorectal cancer, acquired resistance, cetuximab, transcriptome alteration, regulatory networks, 207
- Colorectal cancer, adiponectin, leptin, $\text{tNF-}\alpha$, metabolic syndrome, obesity, NAFLD, 519
- Colorectal cancer, myD88, NF- κ B/MAPK, LPS, inflammatory, 409
- Colorectal cancer, polio virus, the UCSC Genome Browser, the Cancer Genome Atlas, cancer vaccines, 65
- Colorectal cancer, whole exome sequencing, intratumor heterogeneity, patient-derived xenograft, 21
- Cytogenetics, myoid hamartoma of the breast, chromosome translocation, HMGA2 rearrangement, fluorescence *in situ* hybridization, RNA sequencing, reverse transcription polymerase chain reaction, sanger sequencing, 563
- DDR1, miR-199a-5p, miR-199b-5p, clear cell renal cell carcinoma, 179
- Detection, early stage lung cancer, biomarkers, proteomics, immunoassay, diagnosis, non-small cell lung cancer, 229

- Diagnosis, early stage lung cancer, biomarkers, proteomics, immunoassay, detection, non-small cell lung cancer, 229
- Differential gene expression analysis, triple-negative breast cancer, apigenin, tNF α , immune signaling, 421
- Differentially expressed proteins, colon cancer, gene ontology, liver metastatic cancer, mass spectrometry analysis, protein-protein interactions, 583
- Discordance, PTEN immunohistochemistry, heterogeneity, PI3K pathway, hER2-positive breast cancer, adjuvant chemotherapy, trastuzumab, 195
- Drug resistance, melanoma, FOXC2, interferon, tumor progression, 491
- Early stage lung cancer, biomarkers, proteomics, immunoassay, detection, diagnosis, non-small cell lung cancer, 229
- Egfr, claudin, maspin, scca, survivin, vegf, hpv, p16, 155
- EGFR, KRAS, mutations, platinum-based chemotherapy, NSCLC, 531
- Endocrine cancer, mts1, thyroid cancer, prognostic factor, 369
- EPB41L5, pancreatic neuroendocrine tumor, gene expression profile, immunohistochemistry, 309
- Epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, orthotopic), miR inhibition, miR reconstitution of function, target validation, review, 99
- Epithelial ovarian cancer, tumor marker, USP10, p14ARF, 553
- Epithelial–mesenchymal transition (EMT), breast cancer, mesenchymal–epithelial transition (MET), metastasis, chemoresistance, exosomes, 163
- Epithelioid osteoblastoma, COL1A1, FYN, COL1A1-FYN fusion gene, RNA sequencing, 361
- EQTL mapping, vitamin C, leukemia, key genes, alternative pathways, 333
- Exosomes, breast cancer, epithelial–mesenchymal transition (EMT), mesenchymal–epithelial transition (MET), metastasis, chemoresistance, 163
- Fat tissue, periprostatic adipose tissue, secretome, proteomic, prostate cancer, benign prostate hyperplasia, microenvironment, 29
- FIGO-stages I-II, BMI, p27, non-serous tumors, ovarian cancer, 443
- Fluorescence *in situ* hybridization, myoid hamartoma of the breast, chromosome translocation, cytogenetics, HMGA2 rearrangement, RNA sequencing, reverse transcription polymerase chain reaction, sanger sequencing, 563
- FOSB, pseudomyogenic hemangioendothelioma, WWTR1, WWTR1-FOSB fusion gene, RNA sequencing, 293
- FOXC2, melanoma, drug resistance, interferon, tumor progression, 491
- Fusion gene, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, RB1, pseudogene, targetable fusion, 399
- FYN, epithelioid osteoblastoma, COL1A1, COL1A1-FYN fusion gene, RNA sequencing, 361
- Gene expression profile (GEP), ionizing radiation (IR), MDA-MB-231 cells, 257
- Gene expression profile, pancreatic neuroendocrine tumor, EPB41L5, immunohistochemistry, 309
- Gene ontology, colon cancer, differentially expressed proteins, liver metastatic cancer, mass spectrometry analysis, protein-protein interactions, 583
- Gene transfer, senescence, GRIK2, GLUR6, carcinoma, cancer, 59
- Genotype, metastasis, MMP2, nasopharyngeal cancer, susceptibility, polymorphism, taiwan, 287
- GLUR6, senescence, GRIK2, carcinoma, cancer, gene transfer, 59
- Glycerol-3-phosphate dehydrogenase, breast cancer proteomics, monoacylglycerol lipase, 377
- GRIK2, senescence, GLUR6, carcinoma, cancer, gene transfer, 59
- GRP78, hepatocellular carcinoma, sorafenib, resistance, 569
- Head and neck cancer, microRNA, miR-15b-5p, locoregional control, radiotherapy, IMRT, 139
- Hepatocellular carcinoma, sorafenib, resistance, GRP78, 569
- HER2-positive breast cancer, PTEN immunohistochemistry, heterogeneity, discordance, PI3K pathway, adjuvant chemotherapy, trastuzumab, 195
- HERG, microRNA, breast cancer, miR-362-3p, voltage-gated potassium channels, 433
- Heterogeneity, PTEN immunohistochemistry, discordance, PI3K pathway, hER2-positive breast cancer, adjuvant chemotherapy, trastuzumab, 195
- HMGA2 rearrangement, myoid hamartoma of the breast, chromosome translocation, cytogenetics, fluorescence *in situ* hybridization, RNA sequencing, reverse transcription polymerase chain reaction, Sanger sequencing, 563
- Hpv, claudin, maspin, scca, survivin, egfr, vegf, p16, 155
- Immune signaling, triple-negative breast cancer, apigenin, tNF α , differential gene expression analysis, 421
- Immunoassay, early stage lung cancer, biomarkers, proteomics, detection, diagnosis, non-small cell lung cancer, 229
- Immunohistochemistry, pancreatic neuroendocrine tumor, EPB41L5, gene expression profile, 309
- Immunotherapy, non-small cell lung cancer, KRAS, 577
- IMRT, head and neck cancer, microRNA, miR-15b-5p, locoregional control, radiotherapy, 139
- In vivo* metastasis models (experimental, epithelial mesenchymal transition (EMT), spontaneous, intracardiac, orthotopic), miR inhibition, miR reconstitution of function, target validation, review, 99
- In vivo* metastasis models, interference with signaling networks, miR substitution and inhibition, prognostic aspects, pro-metastatic pathways, target validation, review, 1
- Inflammatory, myD88, NF- κ B/MAPK, LPS, colorectal cancer, 409
- Interference with signaling networks, *in vivo* metastasis models, miR substitution and inhibition, prognostic aspects, pro-metastatic pathways, target validation, review, 1
- Interferon, melanoma, FOXC2, drug resistance, tumor progression, 491
- Intracardiac, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, orthotopic), miR inhibition, miR reconstitution of function, target validation, review, 99

- Intratumor heterogeneity, colorectal cancer, whole exome sequencing, patient-derived xenograft, 21
- Invasiveness, breast cancer, proteomics, systems biology, 505
- Ionizing radiation (IR), MDA-MB-231 cells, gene expression profile (GEP), 257
- ITRAQ, cancer-associated adipocytes, CAA, breast cancer, metabolism, tumour microenvironment, 319
- ITRAQ, PBMC, blood, SWATH, pancreatic cancer, 81
- Key genes, vitamin C, leukemia, eQTL mapping, alternative pathways, 333
- KRAS oncogene, antagomirs, miR sponges, orthotopic xenograft models, therapeutic miR-related agents, transforming growth factor β signaling, tumor suppressor genes, review, 451
- KRAS, EGFR, mutations, platinum-based chemotherapy, NSCLC, 531
- KRAS, non-small cell lung cancer, immunotherapy, 577
- Leptin, adiponectin, tNF- α , colorectal cancer, metabolic syndrome, obesity, NAFLD, 519
- Leukemia, vitamin C, eQTL mapping, key genes, alternative pathways, 333
- Liver metastatic cancer, colon cancer, differentially expressed proteins, gene ontology, mass spectrometry analysis, protein-protein interactions, 583
- Locoregional control, head and neck cancer, microRNA, miR-15b-5p, radiotherapy, IMRT, 139
- LPS, myD88, NF- κ B/MAPK, inflammatory, colorectal cancer, 409
- Male breast cancer, proteomics, mass spectrometry, serum biomarkers, 129
- Malignant chondroid syringoma, *PHF1*, *TFE3*, *PHF1-TFE3* fusion gene, RNA sequencing, 345
- Maspin, claudin, scca, survivin, egfr, vegf, hpv, p16, 155
- Mass spectrometry analysis, colon cancer, differentially expressed proteins, gene ontology, liver metastatic cancer, protein-protein interactions, 583
- Mass spectrometry, male breast cancer, proteomics, serum biomarkers, 129
- MDA-MB-231 cells, ionizing radiation (IR), gene expression profile (GEP), 257
- Medullary, colon cancer, MSI, mucinous, STK11, mutation, 267
- Melanoma, FOXC2, drug resistance, interferon, tumor progression, 491
- Mesenchymal-epithelial transition (MET), breast cancer, epithelial-mesenchymal transition (EMT), metastasis, chemoresistance, exosomes, 163
- Metabolic syndrome, adiponectin, leptin, tNF- α , colorectal cancer, obesity, NAFLD, 519
- Metabolism, cancer-associated adipocytes, CAA, iTRAQ, breast cancer, tumour microenvironment, 319
- Metastasis, breast cancer, epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), chemoresistance, exosomes, 163
- Metastasis, genotype, *MMP2*, nasopharyngeal cancer, susceptibility, polymorphism, taiwan, 287
- Metastasis, prostate cancer, mutated peptides, quantitative proteomics, proteogenomics, 273
- Microenvironment, periprostatic adipose tissue, fat tissue, secretome, proteomic, prostate cancer, benign prostate hyperplasia, 29
- MicroRNA, head and neck cancer, miR-15b-5p, locoregional control, radiotherapy, IMRT, 139
- MicroRNA, hERG, breast cancer, miR-362-3p, voltage-gated potassium channels, 433
- MicroRNA, renal cell carcinoma, sunitinib, prediction, 353
- MiR inhibition, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, orthotopic), miR reconstitution of function, target validation, review, 99
- MiR reconstitution of function, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, orthotopic), miR inhibition, target validation, review, 99
- MiR sponges, antagomirs, *KRAS* oncogene, orthotopic xenograft models, therapeutic miR-related agents, transforming growth factor β signaling, tumor suppressor genes, review, 451
- MiR substitution and inhibition, *in vivo* metastasis models, interference with signaling networks, prognostic aspects, pro-metastatic pathways, target validation, review, 1
- MiR-1, osteosarcoma, p21, PAX3, p53-independent pathway, 71
- MiR-15b-5p, head and neck cancer, microRNA, locoregional control, radiotherapy, IMRT, 139
- MiR-199a-5p, DDR1, miR-199b-5p, clear cell renal cell carcinoma, 179
- MiR-199b-5p, DDR1, miR-199a-5p, clear cell renal cell carcinoma, 179
- MiR-362-3p, microRNA, hERG, breast cancer, voltage-gated potassium channels, 433
- MMP2*, genotype, metastasis, nasopharyngeal cancer, susceptibility, polymorphism, taiwan, 287
- Molecular dynamics simulation, mTOR, CASTOR1, cancer, 465
- Monoacylglycerol lipase, breast cancer proteomics, glycerol-3-phosphate dehydrogenase, 377
- MSI, colon cancer, medullary, mucinous, STK11, mutation, 267
- MTOR, CASTOR1, cancer, molecular dynamics simulation, 465
- Mts1, thyroid cancer, endocrine cancer, prognostic factor, 369
- Mucinous carcinoma, CDX2, 5-fluorouracil, REG4, ovarian cancer, 481
- Mucinous, colon cancer, MSI, medullary, STK11, mutation, 267
- Mutated peptides, prostate cancer, metastasis, quantitative proteomics, proteogenomics, 273
- Mutation, colon cancer, MSI, medullary, mucinous, STK11, 267
- Mutation, SF3B1, TET2, myeloid neoplasm, 91
- Mutations, acute myeloid leukemia, trisomy 4, targeted sequencing, *NPM1*, 175
- Mutations, *KRAS*, EGFR, platinum-based chemotherapy, NSCLC, 531
- MyD88, NF- κ B/MAPK, LPS, inflammatory, colorectal cancer, 409

- Myeloid neoplasm, SF3B1, TET2, mutation, 91
- Myoid hamartoma of the breast, chromosome translocation, cytogenetics, HMG2A rearrangement, fluorescence *in situ* hybridization, RNA sequencing, reverse transcription polymerase chain reaction, sanger sequencing, 563
- NAFLD, adiponectin, leptin, tNF- α , colorectal cancer, metabolic syndrome, obesity, 519
- Nasopharyngeal cancer, genotype, metastasis, *MMP2*, susceptibility, polymorphism, taiwan, 287
- Next generation sequencing, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, NGS, recurrence, targetable genetic alterations, 221
- NF- κ B/MAPK, myD88, LPS, inflammatory, colorectal cancer, 409
- NGS, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, next generation sequencing, recurrence, targetable genetic alterations, 221
- Non-serous tumors, BMI, p27, ovarian cancer, FIGO-stages I-II, 443
- Non-small cell lung cancer, early stage lung cancer, biomarkers, proteomics, immunoassay, detection, diagnosis, 229
- Non-small cell lung cancer, *KRAS*, immunotherapy, 577
- NPM1*, acute myeloid leukemia, trisomy 4, targeted sequencing, mutations, 175
- NSCLC, *KRAS*, EGFR, mutations, platinum-based chemotherapy, 531
- Obesity, adiponectin, leptin, tNF- α , colorectal cancer, metabolic syndrome, NAFLD, 519
- Orthotopic xenograft models, antagomirs, *KRAS* oncogene, miR sponges, therapeutic miR-related agents, transforming growth factor β signaling, tumor suppressor genes, review, 451
- Orthotopic, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, miR inhibition, miR reconstitution of function, target validation, review, 99
- Osteosarcoma, miR-1, p21, PAX3, p53-independent pathway, 71
- Ovarian cancer, BMI, p27, non-serous tumors, FIGO-stages I-II, 443
- Ovarian cancer, CDX2, 5-fluorouracil, REG4, mucinous carcinoma, 481
- P14ARF, epithelial ovarian cancer, tumor marker, USP10, 553
- P16, claudin, maspin, scca, survivin, egfr, vegf, hpv, 155
- P21, osteosarcoma, miR-1, PAX3, p53-independent pathway, 71
- P27, BMI, non-serous tumors, ovarian cancer, FIGO-stages I-II, 443
- P53-independent pathway, osteosarcoma, miR-1, p21, PAX3, 71
- Pancreatic cancer, PBMC, blood, iTRAQ, SWATH, 81
- Pancreatic neuroendocrine tumor, EPB41L5, gene expression profile, immunohistochemistry, 309
- Patient-derived xenograft, colorectal cancer, whole exome sequencing, intratumor heterogeneity, 21
- PAX3, osteosarcoma, miR-1, p21, p53-independent pathway, 71
- PBMC, blood, iTRAQ, SWATH, pancreatic cancer, 81
- Periprostic adipose tissue, fat tissue, secretome, proteomic, prostate cancer, benign prostate hyperplasia, microenvironment, 29
- PHF1-TFE3* fusion gene, malignant chondroid syringoma, *PHF1*, *TFE3*, RNA sequencing, 345
- PHF1*, malignant chondroid syringoma, *TFE3*, *PHF1-TFE3* fusion gene, RNA sequencing, 345
- PI3K pathway, PTEN immunohistochemistry, heterogeneity, discordance, hER2-positive breast cancer, adjuvant chemotherapy, trastuzumab, 195
- Platinum-based chemotherapy, *KRAS*, EGFR, mutations, NSCLC, 531
- Pluripotency, telomeres, breast cancer, cell cycle, 121
- Polio virus, colorectal cancer, the UCSC Genome Browser, the Cancer Genome Atlas, cancer vaccines, 65
- Polymorphism, genotype, metastasis, *MMP2*, nasopharyngeal cancer, susceptibility, taiwan, 287
- Prediction, renal cell carcinoma, sunitinib, microRNA, 353
- PRIMA-1^{MET}, cellular senescence, apoptosis, cholangiocarcinoma, 543
- Pro-metastatic pathways, *in vivo* metastasis models, interference with signaling networks, miR substitution and inhibition, prognostic aspects, target validation, review, 1
- Prognostic aspects, *in vivo* metastasis models, interference with signaling networks, miR substitution and inhibition, pro-metastatic pathways, target validation, review, 1
- Prognostic factor, mts1, thyroid cancer, endocrine cancer, 369
- Prostate cancer, metastasis, mutated peptides, quantitative proteomics, proteogenomics, 273
- Prostate cancer, periprostic adipose tissue, fat tissue, secretome, proteomic, benign prostate hyperplasia, microenvironment, 29
- Protein-protein interactions, colon cancer, differentially expressed proteins, gene ontology, liver metastatic cancer, mass spectrometry analysis, 583
- Proteogenomics, prostate cancer, metastasis, mutated peptides, quantitative proteomics, 273
- Proteomic, periprostic adipose tissue, fat tissue, secretome, prostate cancer, benign prostate hyperplasia, microenvironment, 29
- Proteomics, breast cancer, invasiveness, systems biology, 505
- Proteomics, early stage lung cancer, biomarkers, immunoassay, detection, diagnosis, non-small cell lung cancer, 229
- Proteomics, male breast cancer, mass spectrometry, serum biomarkers, 129
- Pseudogene, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, fusion gene, RB1, targetable fusion, 399
- Pseudomyogenic hemangioendothelioma, *WWTR1-FOSB*, *WWTR1-FOSB* fusion gene, RNA sequencing, 293
- PTEN immunohistochemistry, heterogeneity, discordance, PI3K pathway, hER2-positive breast cancer, adjuvant chemotherapy, trastuzumab, 195
- Quantitative proteomics, prostate cancer, metastasis, mutated peptides, proteogenomics, 273
- Radiotherapy, head and neck cancer, microRNA, miR-15b-5p, locoregional control, IMRT, 139

- RB1, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, fusion gene, pseudogene, targetable fusion, 399
- Recurrence, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, next generation sequencing, NGS, targetable genetic alterations, 221
- REG4, CDX2, 5-fluorouracil, mucinous carcinoma, ovarian cancer, 481
- Regulatory networks, acquired resistance, cetuximab, colorectal cancer, transcriptome alteration, 207
- Renal cell carcinoma, sunitinib, microRNA, prediction, 353
- Resistance, hepatocellular carcinoma, sorafenib, GRP78, 569
- Reverse transcription polymerase chain reaction, myoid hamartoma of the breast, chromosome translocation, cytogenetics, HMGA2 rearrangement, fluorescence *in situ* hybridization, RNA sequencing, sanger sequencing, 563
- Review, antagomirs, *KRAS* oncogene, miR sponges, orthotopic xenograft models, therapeutic miR-related agents, transforming growth factor β signaling, tumor suppressor genes, 451
- Review, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, orthotopic), miR inhibition, miR reconstitution of function, target validation, 99
- Review, *in vivo* metastasis models, interference with signaling networks, miR substitution and inhibition, prognostic aspects, pro-metastatic pathways, target validation, 1
- RNA sequencing, epithelioid osteoblastoma, *COL1A1*, *FYN*, *COL1A1-FYN* fusion gene, 361
- RNA sequencing, malignant chondroid syringoma, *PHF1*, *TFE3*, *PHF1-TFE3* fusion gene, 345
- RNA sequencing, myoid hamartoma of the breast, chromosome translocation, cytogenetics, HMGA2 rearrangement, fluorescence *in situ* hybridization, reverse transcription polymerase chain reaction, sanger sequencing, 563
- RNA sequencing, pseudomyogenic hemangioendothelioma, *WWTR1*, *FOSB*, *WWTR1-FOSB* fusion gene, 293
- Sanger sequencing, myoid hamartoma of the breast, chromosome translocation, cytogenetics, HMGA2 rearrangement, fluorescence *in situ* hybridization, RNA sequencing, reverse transcription polymerase chain reaction, 563
- Scca, claudin, maspin, survivin, egfr, vegf, hpv, p16, 155
- Secretome, periprosthetic adipose tissue, fat tissue, proteomic, prostate cancer, benign prostate hyperplasia, microenvironment, 29
- Senescence, GRIK2, GLUR6, carcinoma, cancer, gene transfer, 59
- Serum biomarkers, male breast cancer, proteomics, mass spectrometry, 129
- SF3B1, TET2, mutation, myeloid neoplasm, 91
- Soft tissue sarcoma, undifferentiated pleomorphic sarcoma, next generation sequencing, NGS, recurrence, targetable genetic alterations, 221
- Soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, fusion gene, RB1, pseudogene, targetable fusion, 399
- Sorafenib, hepatocellular carcinoma, resistance, GRP78, 569
- Spontaneous, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, intracardiac, orthotopic), miR inhibition, miR reconstitution of function, target validation, review, 99
- STK11, colon cancer, MSI, medullary, mucinous, mutation, 267
- Sunitinib, renal cell carcinoma, microRNA, prediction, 353
- Survival, breast cancer, von Willebrand factor, the Cancer Genome Atlas, coagulation, 147
- Survivin, claudin, maspin, scca, egfr, vegf, hpv, p16, 155
- Susceptibility, genotype, metastasis, *MMP2*, nasopharyngeal cancer, polymorphism, taiwan, 287
- SWATH, PBMC, blood, iTRAQ, pancreatic cancer, 81
- Systems biology, breast cancer, invasiveness, proteomics, 505
- Taiwan, genotype, metastasis, *MMP2*, nasopharyngeal cancer, susceptibility, polymorphism, 287
- Target validation, epithelial mesenchymal transition (EMT), *in vivo* metastasis models (experimental, spontaneous, intracardiac, orthotopic), miR inhibition, miR reconstitution of function, review, 99
- Target validation, *in vivo* metastasis models, interference with signaling networks, miR substitution and inhibition, prognostic aspects, pro-metastatic pathways, review, 1
- Targetable fusion, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, transcriptome sequencing, fusion gene, RB1, pseudogene, 399
- Targetable genetic alterations, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, next generation sequencing, NGS, recurrence, 221
- Targeted sequencing, acute myeloid leukemia, trisomy 4, mutations, *NPM1*, 175
- Telomeres, pluripotency, breast cancer, cell cycle, 121
- TET2, SF3B1, mutation, myeloid neoplasm, 91
- TFE3*, malignant chondroid syringoma, *PHF1*, *PHF1-TFE3* fusion gene, RNA sequencing, 345
- The Cancer Genome Atlas, breast cancer, survival, von Willebrand factor, coagulation, 147
- The Cancer Genome Atlas, polio virus, colorectal cancer, the UCSC Genome Browser, cancer vaccines, 65
- The UCSC Genome Browser, polio virus, colorectal cancer, the Cancer Genome Atlas, cancer vaccines, 65
- Therapeutic miR-related agents, antagomirs, *KRAS* oncogene, miR sponges, orthotopic xenograft models, transforming growth factor β signaling, tumor suppressor genes, review, 451
- Thyroid cancer, mts1, endocrine cancer, prognostic factor, 369
- TNF- α , adiponectin, leptin, colorectal cancer, metabolic syndrome, obesity, NAFLD, 519
- TNF α , triple-negative breast cancer, apigenin, differential gene expression analysis, immune signaling, 421
- Transcriptome alteration, acquired resistance, cetuximab, colorectal cancer, regulatory networks, 207
- Transcriptome sequencing, soft tissue sarcoma, undifferentiated pleomorphic sarcoma, fusion gene, RB1, pseudogene, targetable fusion, 399

- Transforming growth factor β signaling, antagomirs, *KRAS* oncogene, miR sponges, orthotopic xenograft models, therapeutic miR-related agents, tumor suppressor genes, review, 451
- Trastuzumab, PTEN immunohistochemistry, heterogeneity, discordance, PI3K pathway, hER2-positive breast cancer, adjuvant chemotherapy, 195
- Triple-negative breast cancer, apigenin, $\text{tNF}\alpha$, differential gene expression analysis, immune signaling, 421
- Trisomy 4, acute myeloid leukemia, targeted sequencing, mutations, *NPM1*, 175
- Tumor marker, epithelial ovarian cancer, USP10, p14ARF, 553
- Tumor progression, melanoma, FOXC2, drug resistance, interferon, 491
- Tumor suppressor genes, antagomirs, *KRAS* oncogene, miR sponges, orthotopic xenograft models, therapeutic miR-related agents, transforming growth factor β signaling, review, 451
- Tumour microenvironment, cancer-associated adipocytes, CAA, iTRAQ, breast cancer, metabolism, 319
- Undifferentiated pleomorphic sarcoma, soft tissue sarcoma, next generation sequencing, NGS, recurrence, targetable genetic alterations, 221
- Undifferentiated pleomorphic sarcoma, soft tissue sarcoma, transcriptome sequencing, fusion gene, RB1, pseudogene, targetable fusion, 399
- USP10, epithelial ovarian cancer, tumor marker, p14ARF, 553
- Vegf, claudin, maspin, scca, survivin, egfr, hpv, p16, 155
- Vitamin C, leukemia, eQTL mapping, key genes, alternative pathways, 333
- Voltage-gated potassium channels, microRNA, hERG, breast cancer, miR-362-3p, 433
- Von Willebrand factor, breast cancer, survival, the Cancer Genome Atlas, coagulation, 147
- Whole exome sequencing, colorectal cancer, intratumor heterogeneity, patient-derived xenograft, 21
- WWTR1-FOSB* fusion gene, pseudomyogenic hemangioendothelioma, *WWTR1*, *FOSB*, RNA sequencing, 293
- WWTR1*, pseudomyogenic hemangioendothelioma, *FOSB*, *WWTR1-FOSB* fusion gene, RNA sequencing, 293

Instructions for Authors 2019

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) rational anticancer drug design and drug development. CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt online publication of original works of high quality, generally within 1-2 months of final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal (print or online), and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to CGP will be subject to peer-review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are urgently treated with absolute confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

The Editors and Publishers of CGP accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 800.00 (effective January 1, 2020) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in CGP are the property of the publisher.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods* or *Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalgleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region,

2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC-IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘ISRCTN’). Please note that there is no space between the prefix ‘ISRCTN’ and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iar-anticancer.org. Managing Editor: editor@iar-anticancer.org.

Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Cancer Genomics & Proteomics (CGP) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to CGP is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to CGP, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for CGP:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to CGP may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to CGP.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 67%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org.
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of CGP).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Authors Index

(Figures refer to page numbers)

- Achard V, 577
 Addeo A, 577
 Adile A, 299
 Aejaaz N, 309
 Ahmad P, 139
 Akerud H, 443
 Akpınar G, 377
 Anagnostopoulos AK, 129, 593
 Andersen HK, 563
 Andersen K, 361
 Apprey V, 245
 Assiri AA, 433
 Athwal RS, 59
 Bassarova A, 345
 Bau D-T, 287
 Bauer D, 421
 Beyene D, 245
 Bigagli E, 163
 Birzele F, 1, 99, 451
 Bjerkehaugen B, 361
 Bobos M, 195
 Boulware D, 309
 Brabec P, 353
 Bravatà V, 257
 Bravou V, 593
 Brinkmann U, 1
 Buchler T, 353
 Bushhouse DZ, 491
 Cai W, 399
 Calvo JC, 29
 Camerota TC, 299
 Cammarata FP, 257
 Casamassima P, 519
 Casas G, 29
 Ceausu RA, 299
 Champeris Tsaniras S, 593
 Chang W-S, 287
 Chao C-C, 287
 Chay DB, 553
 Chen Yaowen, 207
 Chen Yuhan, 333
 Chen Yuling, 207
 Cheng Z, 409
 Cheon MG, 369
 Cho H, 553
 Christodoulou C, 195
 Chun SY, 273
 Chung J-Y, 553
 Chung YS, 369
 Cimpean AM, 299
 Cinci L, 163
 Cives M, 309
 Copeland Jr RL, 245
 Coppola D, 267, 309
 Crake RLI, 319
 Currie MJ, 319
 D'Ambrosio M, 163
 Daniele A, 519
 Daremipouran MR, 245
 Daskalaki E, 531
 De Luca R, 519
 Delinasios GJ, 593
 Dembitzer FR, 147
 Divella R, 519
 Dumollard JM, 155
 Dziegiel P, 179
 Efstratiou I, 195, 531
 Eguchi H, 21
 Elgamal M, 505
 Epp A, 1
 Eschrich SA, 309
 Fabian P, 353
 Fazio I, 257
 Feng Y-H, 569
 Fiala O, 353
 Forte GI, 257
 Fountzilas G, 195, 531
 Friedlaender A, 577
 Froudarakis M, 155
 Fu D, 81
 Fujii R, 71
 Gablo NA, 139
 Gadara M, 309
 Gal B, 139
 Gao X, 81
 Gavid M, 155
 Gazouli M, 129
 Giannoulitou E, 195
 Godlewski J, 179
 Goebel C, 229
 Gogas H, 195
 Gong C-L, 287
 Gorunova L, 175, 293, 345, 361, 563
 Green S, 147
 Grzegorzolka J, 179
 Gu W, 333
 Gunes A, 377
 Gurel B, 377
 Gurin D, 139
 Györfy B, 491
 Ha Y-S, 273
 Han GH, 553
 Hargadon KM, 491
 Heim S, 175, 293, 345, 361, 563
 Hermanova M, 139
 Hirata E, 481
 Hoffman RM, 409
 Holth A, 361
 Horakova Z, 139
 Hsu H-M, 287
 Hsu S-W, 287
 Hu S, 207
 Huang Y, 409
 Hussaini M, 91
 Ioiart I, 299
 Jang HH, 369, 583
 Jiang WG, 121
 Johnson CE, 491
 Jung Y, 583
 Juracek J, 353
 Kalogera-Fountzila A, 531
 Kanaan YM, 245
 Kandpal RP, 59
 Karaosmanoglu Yoneten K, 377
 Karavasilis V, 531
 Karpathiou G, 155
 Kasap M, 377
 Kassim OO, 245
 Kazda T, 139
 Kiel P, 433
 Kiewisz J, 179
 Kim E-K, 583
 Kim J-H, 553
 Kim S, 273
 Kittirat Y, 543
 Kleffmann T, 319
 Kmiec Z, 179
 Koh I, 481
 Kopecky J, 353
 Kosmidis PA, 531
 Kostopoulos I, 195
 Kotoula V, 195, 531
 Koutras A, 195
 Kouvateas G, 531
 Kovacova J, 353
 Kowalczyk AE, 179
 Krazinski BE, 179
 Krueger GRF, 465
 Kudo Y, 481
 Kuroda Y, 21
 Kwiatkowski P, 179
 Kwon OK, 273
 Kwon TG, 273
 Lampaki S, 531
 Lazaridis G, 195
 Lee H, 273
 Lee J-H, 369
 Lee JN, 273
 Lee S, 273
 Lee W-S, 583
 Legaki E, 129
 Lehrer S, 65, 147
 Li H, 81
 Li J, 333
 Li T, 207
 Li X, 465
 Li Z, 207
 Lin C, 409
 Lin K-W, 505
 Linardou H, 531
 Liu Wanqing, 433
 Liu Weidong, 333
 Liu X, 81
 Lobmaier I, 293, 361
 Loilome W, 543
 Lømo J, 563
 Long T, 229
 Loudon CL, 229
 Luceri C, 163
 Lund-Iversen M, 345, 361, 563
 Luo X, 399
 Magliocco A, 267
 Manousou K, 195
 Mao J, 465
 Mao Y, 81
 Marei RG, 505
 Marinos E, 129
 Martin TA, 121
 Masuda T, 21
 Mavropoulou X, 531
 Mazza ON, 29
 Mazzanti M, 299
 Mazzio E, 421
 Mazzocca A, 519
 McKenna Jr R, 229
 Micci F, 563
 Mimori K, 21
 Minafra L, 257
 Mokbel K, 121
 Moscinski L, 91
 Mountzios G, 531
 Mourad N, 433
 Mousa H, 505
 Musso R, 257
 Naab TJ, 245
 Nakagawa T, 21
 Namwat N, 543
 Nesiu A, 299
 Niida A, 21
 Nopora A, 99, 451
 Nosaka S, 481

- Onugha O, 229
 Orakzai MMAW, 121
 Osaka E, 71
 Overholser BR, 433
 Pan J, 465
 Panagopoulos A, 593
 Panagopoulos I, 175, 293, 345, 361, 563
 Papadopoulou A, 129
 Papadopoulou K, 195, 531
 Papoudou-Bai A, 195
 Paradiso A, 519
 Pectasides D, 195, 531
 Pedersen TD, 563
 Pentheroudakis G, 195
 Peoc'h M, 155
 Petropoulos M, 593
 Phillips E, 319
 Piyawajanusorn C, 543
 Poprach A, 353
 Porta C, 299
 Prades JM, 155
 Psyrri A, 195
 Pucci G, 257
 Qin D, 267
 Qu Y, 221
 Radova L, 139, 353
 Raica M, 299
 Rallis G, 531
 Ren W, 207
 Res E, 531
 Rheinstein PH, 65, 147
 Risberg B, 175
 Rong J, 333
 Rosenzweig KE, 147
 Ruggieri E, 519
 Russo G, 257
 Ryzhova E, 267
 Sabba C, 519
 Sacca PA, 29
 Saller J, 267, 309
 Samantas E, 531
 Sana J, 139
 Sa-Ngiamwibool P, 543
 Sato K, 21, 71
 Savino E, 519
 Scorticati C, 29
 Seidal T, 443
 Sekine M, 481
 Seydaffan S, 309
 Shahid M, 267, 309
 Shao M, 433
 Shen F, 81
 Shi Y, 221, 399
 Shih L-C, 287
 Shimizu D, 21
 Simone M, 519
 Singh SR, 409
 Skaar TC, 433
 Skirnisdottir I, 443
 Slaby O, 139, 353
 Slampa P, 139
 Slavik M, 139
 Sliwinska-Jewsiewicka A, 179
 Smilek P, 139
 Soliman KFA, 421
 Son YW, 369
 Song J, 91
 Song M-J, 583
 Sotiropoulou M, 195
 Souchelnytskyi N, 505
 Souchelnytskyi S, 505
 Spada M, 257
 Spetalen S, 175
 Stachowitz M-L, 155
 Stathopoulos GT, 593
 Strong EW, 491
 Strosberg JR, 309
 Su Y-C, 569
 Sugimoto J, 481
 Sun L, 465
 Sun W, 465
 Sundstrom-Poromaa I, 443
 Suzuki Y, 21
 Svoboda M, 353
 Syrigos KN, 531
 Tan Z, 207
 Tang N, 399
 Taraviras S, 593
 Tarnai BD, 491
 Televantou D, 531
 Thompson JC, 491
 Timotheadou E, 195
 Titapun A, 543
 Tjønnfjord GE, 175
 Tobo T, 21
 Tokuhashi Y, 71
 Torkildsen S, 175
 Torralvo J, 577
 Tran HTT, 175
 Tsai C-W, 287
 Tsai Y-T, 287
 Tsangaris GT, 129
 Tsao C-J, 569
 Tung C-L, 569
 Utkan NZ, 377
 Villiou M, 593
 Vitagliano G, 29
 Vlachakis D, 593
 Vrettou E, 195
 Wachtel A, 229
 Wang Dapeng, 267
 Wang Duoxi, 465
 Wang G, 465
 Wang J, 221, 399
 Wang T, 399
 Wang Y, 207
 Wang Y-C, 287
 Wazir U, 121
 Weidle UH, 1, 99, 451
 Williams CJ, 491
 Wu J, 207
 Wu T-F, 569
 Xiong Y, 81
 Xu J, 207
 Yan W, 221, 399
 Yang P, 81
 Yang S, 409
 Ye J, 409
 Yi JM, 553
 Ying X, 207
 Yuan Y, 465
 Zagouri F, 129, 195
 Zaramboukas T, 531
 Zhang H, 91
 Zhang J, 207
 Zhang S, 399
 Zhang Wei, 333
 Zhang Wenqi, 333
 Zhang X, 91
 Zhao HH, 81
 Zhawar VK, 59
 Zheng B, 221, 399
 Zheng W, 409
 Zhu G, 409
 Zografos E, 129

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access through High Wire Press, Stanford, USA. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence and reprint orders should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 2295053389, e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org (Managing Editor).

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.